Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
about
Treatment of gastric cancerLaparoscopic gastric cancer surgery: Current evidence and future perspectivesS-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysisIs conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classificationConcurrent apatinib and local radiation therapy for advanced gastric cancer: A case report and review of the literatureS-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysisEfficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatinProgression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer.Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation.CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study.Advancing pharmacological treatment options for advanced gastric cancer.Chemotherapy for advanced gastric cancer.Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions.A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study.Metastatic gastric cancer treatment: Second line and beyond.Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends.Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer
P2860
Q24602875-A69A3EC1-C2DC-4A95-91E4-CB2F54646D6BQ26774648-39F06D03-66A4-433D-815E-C6FA9107C18AQ27002415-B1A3D749-1EFF-4168-9FCA-B0FA808C7821Q28084888-09216CE8-B6D1-4FC0-A842-FBDBAB121462Q30235509-9BD323F0-F6EF-4216-B041-33763C779CE3Q33426501-8AF30137-B29D-4781-B337-D2BC659A2A13Q33433129-2F4E4F64-7FEF-499E-9928-B9D7A521B7FBQ33889328-E7895B6A-7AE9-4CB0-B76F-7CD55A1D01A2Q34093885-C8250872-359C-44C4-B65D-824B44F8BB41Q35541950-D75A7815-64A6-4183-8E6F-96AB234DAD69Q37086087-7C201E34-9433-41CB-AE00-25798921D413Q37530507-B6D1C468-B8A8-4E47-BC62-6CD9025D56B8Q38584644-43BFF8BF-328F-47DB-9C4A-2AABA0B0B1BBQ38604012-7BBF9CCB-A6AF-43A8-A4E2-417222944EF0Q38645728-52E52E82-763F-4A40-B58B-C06CBCEA01A5Q40023074-68D62C62-F763-43E2-AEDC-91E849B322EEQ40085069-909FE762-459A-4768-914B-852A6DC6D03BQ40839618-E7296BAB-F390-43C5-929C-E73B55FFF403Q41195879-5C84E249-D25F-4CEA-ACAF-A63223D6DCB5Q42957434-C42DA90C-697C-44E6-9D29-BDEF0818257AQ47146995-9D059136-ED93-43B4-B060-B06F47929A3CQ47402625-BE24BA35-0E7F-4EBE-816D-B3CFF2A50FDEQ47784630-76572729-6AA1-4D8F-BB34-AA14837E62C4Q52851564-B3C6E90E-2CFB-44F0-BA25-76BD731A8DC1Q53374544-C6BB6B3A-404A-4C64-AD57-25528B482E03Q54970742-911148B7-593C-4899-8E65-44A0733A085DQ55155589-5E78F42D-F739-4406-9AD4-297D353C57ECQ57035043-4841EF0F-3F1C-41E4-BF80-80D10EF4E626
P2860
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@ast
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@en
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@nl
type
label
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@ast
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@en
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@nl
prefLabel
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@ast
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@en
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@nl
P2093
P1476
Combination of cisplatin/S-1 i ...... Advanced Gastric Cancer Study.
@en
P2093
J Y Douillard
M Lichinitser
V Gorbunova
P304
P356
10.1016/J.EJCA.2013.07.003
P577
2013-07-27T00:00:00Z